Clinical Trial Update: Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating elranatamab in patients with clinically high-risk relapsed multiple myeloma after cilta-cel; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myeloma | Phase 2 | Status: RECRUITING